FBT Holdings
31 holdings in the fund's latest file; the data source updated it on Oct 8, 2026.
Top 25 Holdings
| # | Holding | Weight | Shares (as reported) | Value (as reported) |
|---|---|---|---|---|
| 1 | Natera, Inc. | 4.62% | 335,386 | $132.7M |
| 2 | Halozyme Therapeutics, Inc. | 4.58% | 1,188,143 | $131.6M |
| 3 | Illumina, Inc. | 4.43% | 476,004 | $127.5M |
| 4 | Corcept Therapeutics Inc. | 4.10% | 985,377 | $117.9M |
| 5 | Genmab A/S (ADR) | 3.98% | 3,121,944 | $114.4M |
| 6 | BeOne Medicines Ltd. (ADR) | 3.84% | 303,104 | $110.3M |
| 7 | Repligen Corporation | 3.65% | 627,681 | $105.0M |
| 8 | Amgen Inc. | 3.58% | 249,143 | $102.9M |
| 9 | NeoGenomics, Inc. | 3.56% | 6,416,474 | $102.5M |
| 10 | Gilead Sciences, Inc. | 3.56% | 697,344 | $102.4M |
| 11 | Regeneron Pharmaceuticals, Inc. | 3.52% | 136,243 | $101.1M |
| 12 | ADMA Biologics, Inc. | 3.52% | 9,970,973 | $101.1M |
| 13 | Biogen Inc. | 3.51% | 454,617 | $101.0M |
| 14 | argenx SE (ADR) | 3.33% | 103,163 | $95.8M |
| 15 | Vertex Pharmaceuticals Incorporated | 3.28% | 186,520 | $94.3M |
| 16 | BioNTech SE (ADR) | 3.28% | 989,580 | $94.3M |
| 17 | Exelixis, Inc. | 3.26% | 1,602,410 | $93.6M |
| 18 | Bio-Techne Corporation | 3.20% | 1,269,793 | $92.1M |
| 19 | United Therapeutics Corporation | 3.14% | 165,498 | $90.2M |
| 20 | Bruker Corporation | 3.13% | 1,507,431 | $90.0M |
| 21 | Incyte Corporation | 3.06% | 775,742 | $88.0M |
| 22 | BioMarin Pharmaceutical Inc. | 2.94% | 1,531,399 | $84.5M |
| 23 | TG Therapeutics, Inc. | 2.92% | 1,585,019 | $83.9M |
| 24 | Sarepta Therapeutics, Inc. | 2.91% | 4,777,645 | $83.6M |
| 25 | Madrigal Pharmaceuticals, Inc. | 2.86% | 168,689 | $82.3M |
Sector Weights
- Healthcare: 100.00%
Country Weights
- United States: 83.35%
- Switzerland: 3.75%
- Denmark: 3.72%
- Netherlands: 3.33%
- Germany: 3.31%
- Ireland: 2.44%
- Other: 0.11%
Shares, value and weight are as reported in the file, dated by the data source's last update of it (not the date of the positions), never adjusted; a split warning appears only for a split close to or after that date, and its absence does not mean the count is on today's share basis. Weights as the fund reports them. Leveraged and inverse funds list swaps and cash, so weights can be negative or add up past 100.